NCT05640726View on ClinicalTrials.gov

The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

May 1, 2024

Study Completion Date

May 1, 2026

Conditions
Rectal Cancer
Interventions
DRUG

PD-1

Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks

RADIATION

SCRT

Radiotherapy dose: 5×5 Gy

DRUG

Bevacizumab

Participants will receive bevacizumab，5mg/kg，intravenously over 60 - 90 minutes, day 1 of every 2 weeks

DRUG

Oxaliplatin

Participants will receive Oxaliplatin，85mg/m2，day1

DRUG

Calcium folinate

Participants will receive calcium folinate ，400mg/m2，day1

DRUG

5-fluorouracil

Participants will receive 5-fluorouracil ，400mg/m2，day1

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV

NCT05640726 - The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy | Biotech Hunter | Biotech Hunter